Exhibit 4.13.1 AMENDMENT AND AGREEMENT This Amendment and Agreement (this "AMENDMENT"), dated as of April 29, 2005, is entered into by and between EPIXTAR CORP., a Florida corporation (the "COMPANY"), and LAURUS MASTER FUND, LTD., a Cayman Islands...Amendment and Agreement • May 5th, 2005 • Epixtar Corp • Services-computer processing & data preparation • New York
EX-10.17 33 dex1017.htm AMENDMENT AND AGREEMENT WITH ASPHELIA PHARMACEUTICALS, THE REGISTRANT AND OVAMED CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR...Amendment and Agreement • May 5th, 2020 • Hamburg
THIS AMENDMENT AND AGREEMENT (“Amendment”) is made as of January 7, 2011 (“Amendment Effective Date”) by and among Asphelia Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 787 Seventh Avenue, 48th floor, New York, NY 10019, United States (“Asphelia”), Coronado Biosciences Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 45 Rockefeller Plaza, Suite 2000, New York, NY 10111, United States (“Coronado”), and OvaMed GmbH, a company with limited liability organized and existing under the laws of Germany and having its principal office at Kiebitzhörn 33-35, 22885 Barsbuttel, Germany (“OvaMed”). Asphelia, Coronado and OvaMed are sometimes collectively referred to herein as the “Parties”.
EX-10.160 4 dex10160.htm AMENDMENT & AGREEMENT BY AND BETWEEN REGISTRANT & MADAUS GMBH CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE...Amendment and Agreement • May 5th, 2020 • Delaware
THIS AMENDMENT AND AGREEMENT (“Amendment”) is made as of November 3, 2006 (“Amendment Effective Date”) by and between Indevus Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 33 Hayden Avenue, Lexington, MA 02421, United States (“Indevus”), and Madaus GmbH, a successor to Madaus AG, a company with limited liability organized and existing under the laws of Germany and having its principal office at Colonia-Allee 15, 51067 Cologne, Germany (“Madaus”). Indevus and Madaus are collectively referred to herein as the “Parties”.
AMENDMENT AND AGREEMENTAmendment and Agreement • July 6th, 2010 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This AMENDMENT AND AGREEMENT (this “Agreement”) is entered into effective for all purposes as of June 30, 2010 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
AMENDMENT AND AGREEMENTAmendment and Agreement • June 29th, 2010 • RealD Inc. • Radio & tv broadcasting & communications equipment
This Amendment and Agreement (this “Agreement/Amendment”) is made as of June 11, 2010 by RealD Inc., a Delaware corporation and the successor to Real D, a California corporation (the “Company”), each of the undersigned stockholders of the Company (collectively, the “Stockholders”) who are parties to the Amended and Restated Investors’ Rights Agreement of the Company dated as of December 24, 2007 (the “IRA”), and each of Drew Skarupa, Bob Mayson, and Joseph Peixoto (collectively, the “Additional Principals” and, collectively with the Company and the Stockholders, the “Parties”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the IRA if defined therein.
ContractAmendment and Agreement • May 5th, 2020 • New York
<DOCUMENT> <TYPE>EX-10 <SEQUENCE>9 <FILENAME>ex10-28.txt <DESCRIPTION>EXHIBIT 10.28 <TEXT> <PAGE> Exhibit 10.28 PORTIONS OF THIS EXHIBIT MARKED BY *** HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT AND AGREEMENT This Amendment and Agreement ("Agreement") is made and entered into as of June 5, 2003 (the "Execution Date"), by and among Calvin Klein, Inc., a New York corporation with a principal place of business at 205 West 39th Street, New York, New York 10018 ("CKI"), Phillips-Van Heusen Corporation, a Delaware corporation with a principal place of business at 200 Madison Avenue, New York, New York 10016 ("PVH"), Warnaco Inc., a Delaware corporation with a principal place of business at 90 Park Avenue, New York, New York 10016 ("Warnaco"), Calvin Klein Jeanswear Company, a Delaware corporation with a principal place of business at 1385 Broadway, Suite #305, New York, New York 10018 ("CKJ"), and
WITNESSETH:Amendment and Agreement • March 30th, 2000 • Dynagen Inc • In vitro & in vivo diagnostic substances
AMENDMENT AND AGREEMENTAmendment and Agreement • January 5th, 2012 • Yayi International Inc • Dairy products • New York
This AMENDMENT AND AGREEMENT (this “Agreement”) is entered into and is effective for all purposes as of December 31, 2011, by and between Yayi International Inc., a Delaware corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
